PSNL · NASDAQ · Medical - Diagnostics & Research

Personalis (PSNL)

Whole-genome liquid biopsy tests that track cancer recurrence at the molecular level.

$16.45
After hours+0.10 (+0.61%)
At close$16.35(+0.68%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue182020232617211714171522
Cost of revenue151414151712131213151518
Gross profit355895752205
342924252323252725273238
Research & development171413131211131212131516
Selling, general & administrative121212121111121413141822
Other expenses640000000000
Operating income−31−24−19−17−14−18−18−22−23−25−32−34
2−364−252222122
Interest income211112222222
Interest expense000000000000
Other non-operating income−23−6−425−2−2−2−2−2−2−2
Income before tax−29−27−13−13−39−16−16−20−22−24−30−32
Income tax expense000000000000
Net income from continuing operations−29−27−13−13−39−16−16−20−22−24−30−32
Net income−29−27−13−13−39−16−16−20−22−24−30−32
EPS, basic−$0.60−$0.54−$0.26−$0.24−$0.64−$0.23−$0.18−$0.23−$0.24−$0.26−$0.29−$0.30
EPS, diluted−$0.60−$0.54−$0.26−$0.24−$0.64−$0.23−$0.18−$0.23−$0.24−$0.26−$0.29−$0.30
Weighted average shares, basic49495152617387898992104105
Weighted average shares, diluted49495152617387898992104105
EBITDA−26−24−10−10−36−14−13−17−19−21−28−29
Depreciation & amortization333333332222
EBIT−29−27−13−13−39−16−16−20−22−24−30−32